Table 1.

Summary of diagnostic work-up and treatment of patients with aHUS whose serum was used for neutrophil adhesion studies

Patient no.	Genetics	CFH Abs	Treatment
1	Not tested	Positive	None
2	CFH—heterozygous variant of unknown significance (c.3644G>A [p.Arg1215Gln])	Negative	Plasma infusion
3	CFH—heterozygous disease causing mutation (c.3148A>T [p.Asn1050Tyr]) CFHR-3/CFHR-1—homozygous deletion	Positive	Plasma infusion
4	CFHR-3/CFHR-1—homozygous deletion	Positive	Eculizumab
5	C3—homozygous variant of unknown significance (c.304C>G [p.Arg102Gly])	Negative	Eculizumab

Eculizumab treatment followed a weight- and/or age-based standard protocol.

aHUS, atypical hemolytic uremic syndrome; CFH Abs, CFH autoantibodies; DEAP HUS, deficiency of complement factor H-related (CFHR) proteins and CFH autoantibody-positive hemolytic uremic syndrome.